

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30

## Application of observational research methods to real-world studies for rare disease drugs: a scoping review protocol

Yuti P Patel<sup>1</sup>, Lea Ghaddar<sup>1</sup>, Yuqi Lin<sup>1</sup>, Nuzat Karim<sup>1</sup>, Kelvin Chan<sup>2,3</sup>, Lee Dupuis<sup>1,4</sup>, Mina Tadrous<sup>1\*</sup>

1. Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada.
2. Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada.
3. Division of Biostatistics, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
4. The Hospital for Sick Children (SickKids), Toronto, Ontario, Canada

\*Corresponding Author:  
Mina Tadrous  
144 College St.  
Toronto, Ontario  
[mina.tadrous@utoronto.ca](mailto:mina.tadrous@utoronto.ca)

Word count: 3070

Abstract word count: 292

## 31 **Abstract**

32 **Objective:** The primary objective is to identify which observational research methods have been  
33 used in the last 5 years in rare disease drug evaluation and how they are applied to generate  
34 adequate evidence regarding the real-world effectiveness or safety of rare disease drugs.

35  
36 **Background:** Rare disease is an umbrella term for a condition which affects <200,000 people  
37 each year and despite the rarity of these conditions, collectively they encompass approximately  
38 7000 different conditions. With the striking number of rare conditions, many pharmaceutical  
39 manufacturers are introducing an increased number of drugs to treat them. However, due to small  
40 patient populations, heterogeneity and other factors related to rare diseases, there are feasibility  
41 concerns regarding the generation of adequate efficacy and safety evidence using conventional  
42 randomized controlled trials (RCTs). Recently, real-world evidence generated through  
43 observational (or real-world) studies has been proposed to address some of the feasibility  
44 concerns with RCTs by measuring drug effectiveness or safety in the real-world setting.  
45 However, there remain methodological concerns due to a lack of randomization/masking. This  
46 proposed scoping review aims to identify which observational research methods in the last 5  
47 years are used in rare disease drug evaluation to address methodological concerns and how  
48 they're applied to generate evidence on drug effectiveness or safety.

49  
50 **Inclusion criteria:** Articles must be primary observational or real-world studies reporting rare  
51 disease drug effectiveness or safety published between 2018-2023. Literature reviews, meta-  
52 analyses, randomized control trials, case series, case reports, opinion pieces, conference  
53 abstracts, and studies with unavailable full-text articles will be excluded.

54 **Methods:** The search strategy will combine the following key search concepts: rare disease,  
55 drugs for rare disease and observational/real-world studies. The search will be conducted in  
56 MEDLINE and EMBASE.

57

58 **Review registration number:** Open Science Framework, <https://osf.io/f3wpy>

59

60 **Keywords:** Rare disease drug, Observational research methods, real-world studies

61

## 62 **Introduction**

63 A rare disease, also referred to as an orphan disease, is a medical condition that affects a small  
64 proportion of the population. Currently, an international consensus on the definition of a rare  
65 disease does not exist. For example, in Canada and the European Union, a rare disease is defined  
66 as a condition that affects fewer than 1 in 2,000 people, while in the United States, it is considered  
67 rare if it affects fewer than 200,000 people. By these definitions, approximately 7,000 different  
68 conditions qualify as rare diseases, resulting in upwards of 300 million people worldwide being  
69 affected(1–4). With a striking number of rare diseases and people affected, the USA and European  
70 Commissions implemented the Orphan Drug Act (ODA) in 1983, and Orphan Medicinal Products  
71 (OMP) in 2000 to incentivize pharmaceutical manufacturers to develop drugs for rare diseases  
72 (3,5,6). Despite orphan drug incentives being in place for many decades, it is in recent years that  
73 an increasing number of drugs for treating rare diseases have been developed. Orphan drug  
74 approvals increased from 14 in 2000 to 77 in 2017, and as of recently in 2022, nearly half of all  
75 new drug approvals by the FDA were for a rare condition(7).

76 With respect to drug evaluation, there are data and statistical constraints to generating adequate  
77 evidence on the benefits of a therapy for treating a rare disease.(1) From the perspective of drug  
78 regulatory and health technology assessment bodies, randomized controlled trials (RCT) are the  
79 “gold standard” to evaluate the efficacy and safety of a drug in a particular patient population(8,9).  
80 RCTs are typically designed prospectively, double blinded and randomized, providing equal  
81 chance for all patients being allocated to the active treatment or comparator and reduces the extent  
82 of bias(9). The controlled environment of an RCT allows for hypotheses to be tested, though,  
83 results from the RCT can only be extrapolated to patients represented in the trial; thus, there are  
84 limitations regarding generalizability of results(8). Additionally, statistical analysis plans for RCTs

85 require an adequate number of patients to statistically power the study(8). Given the nature of rare  
86 diseases, conventional drug evaluations such as RCTs are most often not feasible due to the small  
87 patient populations and heterogeneity in the manifestation of the rare disease. These challenges  
88 are not unique to rare diseases; however, the limited number of patients amplifies these challenges  
89 and presents methodological challenges (1,10).

90 Given the difficulties in conducting RCT for rare diseases, Real-World Evidence (RWE) has  
91 emerged as a viable solution for producing clinical evidence related to the utilization, as well as  
92 the potential advantages or risks of a treatment, derived from an analysis of real-world data  
93 (RWD)(11,12). Based on the FDA definition, RWD is “data relating to patient health status and/or  
94 the delivery of health care routinely collected from a variety of sources” and can be collected  
95 prospectively/retrospectively through observational studies to generate RWE(11,12).  
96 Observational studies such as cohort, case-control, and cross-sectional designs have a well-  
97 established history of use in drug research. They contribute valuable insights into real-world drug  
98 effectiveness or safety, drug utilization patterns, serve to augment the outcomes of RCTs and  
99 overall complement the findings of an RCT to provide a more comprehensive view of a drug's  
100 performance(1,10,11). In the specific context of rare disease drug evaluation, RWE obtained from  
101 observational studies has the potential to address issues associated with limited sample sizes and  
102 the generalizability concerns. However, given the absence of randomization and blinding in  
103 observational studies, there are methodological concerns regarding the validity of results due to  
104 the potential presence of confounding or selection bias(1,10). While there have been research  
105 methods introduced to address these issues, there remains a lack of consistency in their application  
106 with respect to rare disease drug evaluation and ultimately the quality of RWE for decision-  
107 making. With the widespread adoption of RWE in rare disease drug research, regulatory decision-

108 making, and drug policy over the past 5 years, it is imperative to understand how established  
109 observational research methodologies have been incorporated to address methodological  
110 challenges such as the presence of confounders and small patient populations. This understanding  
111 will aid in informing the appropriate and consistent application of observational research methods  
112 to adequately generate RWE for rare disease drugs moving forward. To address this knowledge  
113 gap, the proposed scoping review aims to identify in the last 5 years, which observational research  
114 methods are being utilized in rare disease RWE drug evaluation and how they're applied to  
115 generate adequate evidence regarding the real-world effectiveness or safety.

## 116 **Review Questions**

117 In the last 5 years, how have observational research methods been used in the generation of  
118 RWE on the safety or effectiveness of drugs used to treat rare disease?

- 119 a) Which research methods are being utilized to account for potential confounders or small  
120 sample sizes in observational research/studies for rare disease drug research?
- 121 b) How are the research methods identified being applied to generate drug safety or  
122 effectiveness in the real-world setting?
- 123 c) Which rare diseases are being studied in observational research/studies in the last 5  
124 years?

## 125 **Inclusion Criteria**

### 126 **Participants**

127 This review will focus on rare diseases, drugs for rare disease, orphan diseases, and orphan disease  
128 drugs. Rare disease will be defined in accordance with Health Canada, as a condition that affects  
129 fewer than 1 in 2,000 people (13).

## 130 **Concept**

131 This proposed scoping review will consider observational research on rare disease drug  
132 effectiveness and/or safety.

## 133 **Context**

134 This review will examine studies using health administrative data from all healthcare settings and  
135 regions in the last 5-years.

## 136 **Types of sources**

137 For this scoping review, published and unpublished observational studies (i.e. cohort, case-control  
138 and cross-sectional designs) also referred to as real-world studies, between 2018- 2023 will be  
139 included.

140

## 141 **Exclusion Criteria**

142 Studies that do not evaluate an intervention to treat a rare disease based on the definition above;  
143 do not use health administrative data; published on or before Dec 31, 2017 in a language other  
144 than English; literature reviews (i.e. systematic, scoping, narrative, etc.), meta-analyses,  
145 randomized control trials, case series and case reports, study protocols, opinion pieces (i.e.  
146 editorials, commentaries, letters, etc.), conference abstracts, and studies with unavailable full-text  
147 articles will be excluded.

148

## 149 **Methods**

### 150 **Information Sources**

151 A structured search will be conducted in MEDLINE and EMBASE. A supplementary search of  
152 reference lists of included articles and relevant literature searches will be conducted to identify  
153 any additional relevant articles that may have been missed by the search strategy. Reporting will  
154 be done in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-  
155 Analyses extension for Scoping Reviews (PRISMA-ScR) reporting guidelines.(14)

156

### 157 **Search Strategy**

158 To initiate the search strategy, a preliminary limited search of MEDLINE was undertaken to  
159 identify relevant articles on the topic. The preliminary search indicated the selection of the  
160 following key search concepts: rare diseases/ rare disease drugs and observational/real-world  
161 studies used in the search strategy. During the preliminary search, it was found that terms like real-  
162 world evidence, real-world data, and real-world studies were used interchangeably with  
163 established terms like observational studies/observational research. To ensure a comprehensive  
164 search study, these concepts were treated as synonyms in this review. Moreover, to ensure the  
165 relevance and timeliness of this review, a 5-year timeframe was integrated into this scoping review,  
166 considering the recent issuance of RWE guidance documents by various agencies(15). Upon the  
167 selection of the search concepts, the titles and abstracts of relevant articles were scanned to select  
168 subject headings and text words used to develop the search strategy for MEDLINE (see Appendix  
169 1). The subject headings, text words and keyword queries as well as other database specific syntax  
170 will be adapted for EMBASE.

171



## 172 **Study Records**

### 173 **Data Management**

174 After conducting searches in both MEDLINE and EMBASE, all identified citations will be  
175 transferred to Covidence Systematic Review Software (Veritas Health Innovation in Melbourne,  
176 Australia), for screening. To eliminate duplicate citations, we will employ the Bramer de-  
177 duplication method(16). The study selection process will be facilitated through the Covidence  
178 Systematic Review Software. Additionally, the data collection process will be managed using  
179 Microsoft Excel.

180

### 181 **Selection Process**

#### 182 **Title and Abstract Screening**

183 To ensure accuracy and consistency in the screening process, two independent reviewers will  
184 screen the titles and abstracts of a test set of articles based on the inclusion criteria. Titles and  
185 abstracts of articles that do not meet the inclusion criteria will be excluded, and any disagreements  
186 or potential modifications to the eligibility criteria will be deliberated by the reviewers. The  
187 interrater agreement between the two independent reviewers will be computed using Microsoft  
188 Excel and if 80% agreement is obtained between the two reviewers, the remaining articles will be  
189 screened independently by the two reviewers. If the agreement percentage falls below 80%, the  
190 study team will review and refine the criteria as well as retrain screeners, as necessary(17). They  
191 will then conduct a second round of screening with a new subset of articles until a satisfactory  
192 level of agreement is attained. The full-text for articles that potentially meet the criteria will be  
193 downloaded and imported into Covidence Systematic Review Software for full-text screening.

## 194 **Full-text Screening**

195 The full texts of the articles that successfully passed the screening will undergo a comprehensive  
196 evaluation against the inclusion criteria, conducted by two independent reviewers. If any article is  
197 found not to meet the inclusion criteria, the rationale for its exclusion will be documented. Any  
198 discrepancies between the reviewers will be addressed through discussion and resolved with the  
199 input of a third reviewer. The outcomes of the search and study selection process will be outlined  
200 in the final scoping review using a flow diagram in accordance with the Preferred Reporting Items  
201 for Systematic Reviews and Meta-analyses extension for scoping review (PRISMA-ScR)  
202 guidelines(14).

## 203 **Data Extraction**

204 Using Microsoft Excel, a data extraction form will be created to record necessary information from  
205 all included articles. Prior to the actual data extraction, both reviewers will test the data extraction  
206 form on a subset of articles to ensure consistent and accurate data retrieval. Once a consensus is  
207 established, both reviewers will independently extract data from the remaining articles within the  
208 same set of included articles. To maintain consistency, a third reviewer will perform random spot  
209 checks on 5% of the included articles.

210

211 The extracted data variables will include general article characteristics (i.e., year, authors, journal,  
212 etc.), study design, rare disease studied, rare disease drug studied and its characteristics (i.e.,  
213 formulation, drug class), data sources, observational research methods undertaken including the  
214 authors' rationale for the choice of methods, outcomes including how they were defined and  
215 measured, key findings, conclusions, and funding sources(ie. industry, academic, government etc).

216 A draft extraction tool is provided (see Appendix 2). If required, the data extraction tool will be

217 iteratively modified as necessary early during the extraction process, and modification will be  
218 detailed in the final scoping review. Any disagreements between the two reviewers will be resolved  
219 through discussion with a third reviewer. With respect to missing data, the authors of the paper  
220 will be contacted and requested to provide additional information. In cases where the data cannot  
221 be obtained, the absence of that information will be documented as 'unreported.'

## 222 **Data Analysis and Presentation**

223 A descriptive quantitative analysis of the included articles will be conducted using Microsoft  
224 Excel, alongside a qualitative analysis of appropriate variables as captured in the extraction tool.  
225 Data for the first review question will quantify the frequency of each observational research  
226 method discussed in the included studies. Data for the second review question will reflect the  
227 frequency counts regarding the rationale of method selection and how its application addressed the  
228 methodological concerns with the rare disease being studied. Data for the third review question  
229 will quantify the frequency of each rare disease discussed in the included studies. The outcomes  
230 of the search and the process of including studies will be visually represented in a PRISMA flow  
231 diagram as per reference(14). The relevant data gathered during the extraction will be illustrated  
232 in suitable tables and figures, serving to highlight the current evidence and knowledge gaps in  
233 literature. A descriptive summary of how observational research methods included in the review  
234 were applied to generate the health outcomes of interest will be included with the tabular results.  
235 The findings from this scoping review will support researchers in understanding which  
236 observational research methods can be applied to certain rare disease drug studies to overcome  
237 methodological challenges to obtain RWE on drug effectiveness or safety.

## 238 Reference:

- 239 1. Gagne JJ, Thompson L, O’Keefe K, Kesselheim AS. Innovative research methods for  
240 studying treatments for rare diseases: methodological review. *BMJ*. 2014 Nov  
241 24;349(nov24 15):g6802–g6802.
- 242 2. Yates N, Hinkel J. The economics of moonshots: Value in rare disease drug development.  
243 *Clin Transl Sci*. 2022 Apr 25;15(4):809–12.
- 244 3. Groft SC, Posada M, Taruscio D. Progress, challenges and global approaches to rare  
245 diseases. *Acta Paediatr*. 2021 Oct 19;110(10):2711–6.
- 246 4. Gupta S. Rare diseases: Canada’s ‘research orphans’. *Open Med*. 2012;6(1):e23-7.
- 247 5. Herder M. What Is the Purpose of the Orphan Drug Act? *PLoS Med*. 2017 Jan  
248 3;14(1):e1002191.
- 249 6. European Parliament and of the Council. Regulation (EC) No 141/2000 of the European  
250 Parliament and of the Council of 16 December 1999 on orphan medicinal products.  
251 Brussels; 2000 [Internet]. [cited 2023 Nov 11]. Available from: [https://eur-](https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32000R0141)  
252 [lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32000R0141](https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32000R0141)
- 253 7. Fermaglich LJ, Miller KL. A comprehensive study of the rare diseases and conditions  
254 targeted by orphan drug designations and approvals over the forty years of the Orphan  
255 Drug Act. *Orphanet J Rare Dis*. 2023 Jun 23;18(1):163.
- 256 8. Suvarna V. Real world evidence (RWE) - Are we (RWE) ready? *Perspect Clin Res*.  
257 2018;9(2):61.
- 258 9. Abrahamyan L, Feldman BM, Tomlinson G, Faughnan ME, Johnson SR, Diamond IR, et  
259 al. Alternative designs for clinical trials in rare diseases. *Am J Med Genet C Semin Med*  
260 *Genet*. 2016 Dec 14;172(4):313–31.
- 261 10. Whicher D, Philbin S, Aronson N. An overview of the impact of rare disease  
262 characteristics on research methodology. *Orphanet J Rare Dis*. 2018 Dec 19;13(1):14.
- 263 11. Wu J, Wang C, Toh S, Pisa FE, Bauer L. Use of real-world evidence in regulatory  
264 decisions for rare diseases in the United States—Current status and future directions.  
265 *Pharmacoepidemiol Drug Saf*. 2020 Oct 30;29(10):1213–8.
- 266 12. Liu J, Barrett JS, Leonardi ET, Lee L, Roychoudhury S, Chen Y, et al. Natural History  
267 and Real-World Data in Rare Diseases: Applications, Limitations, and Future  
268 Perspectives. *The Journal of Clinical Pharmacology*. 2022 Dec 3;62(S2).
- 269 13. Government of Canada- Health Canada. Building a National Strategy for High-Cost Drugs  
270 for Rare Diseases: A Discussion Paper for Engaging Canadians. 2021.
- 271 14. Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D, et al. PRISMA  
272 Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. *Ann Intern*  
273 *Med*. 2018 Oct 2;169(7):467–73.
- 274 15. The Canadian Agency for Drugs and Technologies in Health. Guidance for Reporting  
275 Real-World Evidence . 2023.
- 276 16. Bramer WM, Giustini D, de Jonge GB, Holland L, Bekhuis T. De-duplication of database  
277 search results for systematic reviews in EndNote. *J Med Libr Assoc*. 2016 Jul;104(3):240–  
278 3.
- 279 17. McHugh ML. Interrater reliability: the kappa statistic. *Biochem Med (Zagreb)*.  
280 2012;22(3):276–82.

281

282

## 283 **Appendix 1: Search Strategy**

### 284 **MEDLINE**

285 Search conducted on Oct 31, 2023

1	exp Rare Diseases/	14098
2	exp Orphan Drug Production/	1483
3	((rare or orphan) adj2 disease*).tw,kf.	49303
4	((rare or orphan) adj2 drug*).tw,kf.	2751
5	or/1-4 [**rare disease]	60722
6	exp Observational Studies as Topic/	9100
7	exp Retrospective Studies/	1152042
8	((observational adj2 stud*) or research).tw,kf.	2311724
9	or/6-8 [**Observational research]	3381917
10	real-world evidence.mp.	4876
11	real-world data.mp.	10904
12	real-world stud*.mp.	4475
13	or/10-12 [**real-world studies]	18495
14	9 or 13	3392850
15	5 and 14	8716
16	limit 15 to yr="2018 -Current"	4645

286

### 287 **EMBASE**

288 Search conducted on Oct 31, 2023

1	exp Rare Diseases/	50479
2	exp Orphan Drug Production/	3910
3	((rare or orphan) adj2 disease*).tw,kf.	80088
4	((rare or orphan) adj2 drug*).tw,kf.	5308
5	or/1-4 [**rare disease]	112389
6	exp Observational Studies as Topic/	342056
7	exp Retrospective Studies/	1512126
8	((observational adj2 stud*) or research).tw,kf.	3041887
9	or/6-8 [**Observational research]	4490980
10	real-world evidence.mp.	9260
11	real-world data.mp.	21416
12	real-world stud*.mp.	8584
13	or/10-12 [**real-world studies]	36056
14	9 or 13	4508418

15	5 and 14	16656
16	limit 15 to yr="2018 -Current"	9590

## 290 Appendix 2: Data Extraction Form

<b>General article information</b>	
Title	
First Authors	
Journal	
Year	
DOI	
Country(s)	
Continent	
Funding source(s)	
<b>Study overview</b>	
Study design	
Rare disease being studied	
Rare disease intervention being used	
Characteristics of the intervention	
Primary study aim/objective	
<b>Data sources</b>	
Data sources used	
Healthcare setting	
<b>Methodology</b>	
Observational research method(s) used	
Authors' rationale for use of the method(s)	
<b>Outcomes</b>	
Outcomes being measured	
How are the outcomes defined	
How are the outcomes measured	
<b>Results</b>	
Summary of key findings	
Conclusions	